0

    536565

    NOVELIX

    img img img img
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    NOVELIX PHARMACEUTICALS LIMITE Share Price Today

    Investment Returns

    Over 1 Month -24.68% Over 3 Months 12.68% Over 6 Months 17.82% Over 1 Year 38.27%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    NOVELIX PHARMACEUTICALS LIMITE fundamentals


    • Market cap (Cr) [-]
    • P/E Ratio (TTM) [-]
    • Beta [-]
    • Book Value / share [-]
    • Return on equity [-]%
    • EPS (TTM) [-]
    • Dividend yield [-]%
    • Net profit/quarter (Cr) [-]
    info icon alternate text
    • Market cap (Cr) 180.10
    • P/E Ratio (TTM) 70.29
    • Beta 0.51
    • Book Value / share 23.07
    • Return on equity 0.56%
    • EPS (TTM) 0.90
    • Dividend yield [-]%
    • Net profit/quarter (Cr) 0.91
    info icon alternate text

    NOVELIX PHARMACEUTICALS LIMITE Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 25.19
    Operating Expense 23.96
    Net Profit 0.91
    Net Profit Margin (%) 3.61
    Earnings Per Share (EPS) 0.43
    EBITDA 1.28
    Effective Tax Rate (%) 26.01
    Particulars DEC 2025 (Values in Cr)
    Revenue 48.40
    Operating Expense 47.12
    Net Profit 1.00
    Net Profit Margin (%) 2.06
    Earnings Per Share (EPS) 0.58
    EBITDA 1.31
    Effective Tax Rate (%) 21.87
    Particulars SEP 2025 (Values in Cr)
    Revenue 36.36
    Operating Expense 35.67
    Net Profit 0.53
    Net Profit Margin (%) 1.45
    Earnings Per Share (EPS) 0.37
    EBITDA 0.73
    Effective Tax Rate (%) 26.38
    Particulars JUN 2025 (Values in Cr)
    Revenue 22.35
    Operating Expense 22.18
    Net Profit 0.11
    Net Profit Margin (%) 0.49
    Earnings Per Share (EPS) 0.09
    EBITDA 0.18
    Effective Tax Rate (%) 35.29
    Particulars MAR 2025 (Values in Cr)
    Revenue 20.86
    Operating Expense 20.65
    Net Profit 0.18
    Net Profit Margin (%) 0.86
    Earnings Per Share (EPS) 0.18
    EBITDA 0.22
    Effective Tax Rate (%) 14.28
    Particulars MAR 2026 (Values in Cr)
    Revenue 132.31
    Operating Expense 128.93
    Net Profit 2.56
    Net Profit Margin (%) 1.93
    Earnings Per Share (EPS) 1.21
    EBITDA 3.50
    Effective Tax Rate (%) 25.00
    Particulars MAR 2025 (Values in Cr)
    Revenue 30.72
    Operating Expense 30.61
    Net Profit 0.08
    Net Profit Margin (%) 0.26
    Earnings Per Share (EPS) 0.08
    EBITDA 0.16
    Effective Tax Rate (%) 33.33
    Particulars MAR 2024 (Values in Cr)
    Revenue 4.22
    Operating Expense 4.51
    Net Profit 0.01
    Net Profit Margin (%) 0.23
    Earnings Per Share (EPS) 0.01
    EBITDA 0.06
    Effective Tax Rate (%) 50.00
    Particulars MAR 2023 (Values in Cr)
    Revenue 1.40
    Operating Expense 1.98
    Net Profit -0.06
    Net Profit Margin (%) -4.28
    Earnings Per Share (EPS) -0.07
    EBITDA 0.00
    Effective Tax Rate (%) 0.00
    Particulars MAR 2022 (Values in Cr)
    Revenue 0.84
    Operating Expense 2.96
    Net Profit -1.56
    Net Profit Margin (%) -185.71
    Earnings Per Share (EPS) -1.93
    EBITDA -1.50
    Effective Tax Rate (%) 0.63
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 9.14
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.01
    EBITDA Margin -20.22
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 8.47
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.04
    EBITDA Margin -36.18
    Particulars MAR 2020 (Values in Cr)
    Book Value / Share 13.09
    ROE % -2.42
    ROCE % -0.86
    Total Debt to Total Equity 0.08
    EBITDA Margin 0.92
    Particulars MAR 2019 (Values in Cr)
    Book Value / Share 13.48
    ROE % -1.54
    ROCE % -0.93
    Total Debt to Total Equity 0.09
    EBITDA Margin 1.00
    Particulars MAR 2018 (Values in Cr)
    Book Value / Share 13.79
    ROE % -2.99
    ROCE % -0.07
    Total Debt to Total Equity 0.09
    EBITDA Margin 2.16
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 17.63
    ROE % 0.56
    ROCE % 0.84
    Total Debt to Total Equity 0.00
    EBITDA Margin 0.52
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 9.08
    ROE % 0.12
    ROCE % 0.24
    Total Debt to Total Equity 0.00
    EBITDA Margin 1.42
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 8.88
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.00
    EBITDA Margin 0.00
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 8.94
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.00
    EBITDA Margin -107.19
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 10.87
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.00
    EBITDA Margin -243.51
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 2.88
    Total Assets 8.73
    Total Liabilities 8.73
    Total Equity 7.67
    Share Outstanding 0
    Price to Book Ratio 0.99
    Return on Assets (%) -20.60
    Return on Capital (%) -23.05
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 2.07
    Total Assets 9.57
    Total Liabilities 9.57
    Total Equity 7.36
    Share Outstanding 0
    Price to Book Ratio 0.62
    Return on Assets (%) -39.06
    Return on Capital (%) -50.77
    Particulars MAR 2020 (Values in Cr)
    Cash & Short Term Investments 1.11
    Total Assets 13.72
    Total Liabilities 13.72
    Total Equity 11.12
    Share Outstanding 0
    Price to Book Ratio 0.13
    Return on Assets (%) -2.06
    Return on Capital (%) -2.38
    Particulars MAR 2019 (Values in Cr)
    Cash & Short Term Investments 0.19
    Total Assets 13.34
    Total Liabilities 13.34
    Total Equity 11.42
    Share Outstanding 0
    Price to Book Ratio 0.00
    Return on Assets (%) -1.81
    Return on Capital (%) -1.96
    Particulars MAR 2018 (Values in Cr)
    Cash & Short Term Investments 0.35
    Total Assets 13.57
    Total Liabilities 13.57
    Total Equity 11.57
    Share Outstanding 0
    Price to Book Ratio 0.52
    Return on Assets (%) -2.56
    Return on Capital (%) -2.77
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 0.67
    Total Assets 27.20
    Total Liabilities 27.20
    Total Equity 17.53
    Share Outstanding 0
    Price to Book Ratio 1.51
    Return on Assets (%) 0.31
    Return on Capital (%) 0.48
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 0.11
    Total Assets 7.36
    Total Liabilities 7.36
    Total Equity 7.35
    Share Outstanding 0
    Price to Book Ratio 1.89
    Return on Assets (%) 0.14
    Return on Capital (%) 0.14
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 0.27
    Total Assets 7.25
    Total Liabilities 7.25
    Total Equity 7.19
    Share Outstanding 0
    Price to Book Ratio 1.01
    Return on Assets (%) -0.82
    Return on Capital (%) -0.83
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 2.60
    Total Assets 7.25
    Total Liabilities 7.25
    Total Equity 7.24
    Share Outstanding 0
    Price to Book Ratio 0.99
    Return on Assets (%) -21.51
    Return on Capital (%) -21.54
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 1.73
    Total Assets 8.76
    Total Liabilities 8.76
    Total Equity 8.80
    Share Outstanding 0
    Price to Book Ratio 0.62
    Return on Assets (%) -37.28
    Return on Capital (%) -37.13
    Particulars MAR 2022 (Values in Cr)
    Net Income -2.12
    Cash from Operations 1.10
    Cash from Investing -0.75
    Cash from Financing 0.00
    Net change in Cash 0.82
    Free Cash Flow 2.90
    Particulars MAR 2021 (Values in Cr)
    Net Income -3.72
    Cash from Operations 1.62
    Cash from Investing 0.13
    Cash from Financing -0.76
    Net change in Cash 0.96
    Free Cash Flow 1.64
    Particulars MAR 2020 (Values in Cr)
    Net Income -0.21
    Cash from Operations 0.73
    Cash from Investing 0.45
    Cash from Financing -0.16
    Net change in Cash 0.91
    Free Cash Flow 0.83
    Particulars MAR 2019 (Values in Cr)
    Net Income -0.12
    Cash from Operations -0.52
    Cash from Investing 0.42
    Cash from Financing -0.04
    Net change in Cash -0.15
    Free Cash Flow -0.38
    Particulars MAR 2018 (Values in Cr)
    Net Income -0.30
    Cash from Operations 0.49
    Cash from Investing -0.63
    Cash from Financing 0.02
    Net change in Cash -0.24
    Free Cash Flow 0.86
    Particulars MAR 2025 (Values in Cr)
    Net Income 0.12
    Cash from Operations -13.68
    Cash from Investing 2.93
    Cash from Financing 11.31
    Net change in Cash 0.56
    Free Cash Flow -13.57
    Particulars MAR 2024 (Values in Cr)
    Net Income 0.02
    Cash from Operations -0.34
    Cash from Investing 0.18
    Cash from Financing 0.00
    Net change in Cash -0.15
    Free Cash Flow -0.34
    Particulars MAR 2023 (Values in Cr)
    Net Income -0.05
    Cash from Operations -2.40
    Cash from Investing 0.07
    Cash from Financing 0.00
    Net change in Cash -2.33
    Free Cash Flow -2.40
    Particulars MAR 2022 (Values in Cr)
    Net Income -1.56
    Cash from Operations 0.59
    Cash from Investing 0.27
    Cash from Financing 0.00
    Net change in Cash 0.86
    Free Cash Flow 2.45
    Particulars MAR 2021 (Values in Cr)
    Net Income -3.27
    Cash from Operations 0.58
    Cash from Investing 0.20
    Cash from Financing 0.00
    Net change in Cash 0.78
    Free Cash Flow 0.88
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 30.96 12.85 1.49 237.26 23.12 38.85
    BLISS GVS PHARMA LTD 482.50 38.79 4.28 5117.21 118.35 552.90
    CIPLA LTD 1418.40 30.10 3.32 114584.78 1165.55 1672.20
    FERMENTA BIOTECH LIMITED 431.50 19.03 3.12 1269.95 256.40 480.00
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 30.96 21.65 3.98 237.26 23.12 38.85
    AMRUTANJAN HEALTH CARE LTD. 537.90 24.11 4.20 1555.10 490.00 789.95
    ASTRAZENECA PHARMA IND LT 8025.95 104.82 22.98 20064.88 7630.00 9850.00
    BLISS GVS PHARMA LTD 482.50 52.16 4.42 5117.21 118.35 552.90

    NOVELIX PHARMACEUTICALS LIMITE shareholding pattern

    Holding
    49.43%
    50.56%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    NOVELIX PHARMACEUTICALS LIMITE Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    63.26 -4.88 redarrow
    red-green-graph indicator
    14 Bearish
    2 Bullish
    • 5 Days 66.80
    • 26 Days 70.70
    • 10 Days 68.90
    • 50 Days 68.20
    • 12 Days 69.60
    • 100 Days 63.90
    • 20 Days 70.80
    • 200 Days 57.00
    67.67 PIVOT
    First Support 65.35 First Resistance 68.84 Second Support 64.18 Second Resistance 71.16 Third Support 61.86 Third Resistance 72.33
    RSI 37.40 ADX 28.37 MACD -1.13 Williams % R -99.60 Commodity Channel Index (CCI) -116.81
    Date 2026-07-17 Week 4905.00 Same Day 4372.00 Month 6474.00
    1 Year 0.51 3 Year 0.34
    Over 1 Month
    -24.68% down
    Over 1 Year
    38.27% down
    Over 3 Months
    12.68% down
    Over 3 Years
    85.75% down
    Over 6 Months
    17.82% down
    Over 5 Years
    48.94% down

    NOVELIX PHARMACEUTICALS LIMITE Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    16 Aug 2012 0.3 Final 21 Aug 2012 Equity shares
    22 Sep 2011 0.3 Final 25 Sep 2011 Equity shares
    23 Aug 2010 0.03 Final 25 Aug 2010 Equity shares
    01 Sep 2009 0.3 Final 03 Sep 2009 Equity shares
    Ex-Date Old FV NEW FV Record Date
    04 Oct 2010 1.0 10.0 05 Oct 2010
    15 Oct 2009 10.0 1.0 16 Oct 2009

    Top Gainers

    Top Losers

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Novelix Pharmaceuticals Ltd?

    Answer Field

    Novelix Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 63.26 as on Jul 20 2026 09:57 AM.

    What is the Market Cap of Novelix Pharmaceuticals Ltd Share?

    Answer Field

    The market cap of Novelix Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 180.10 as on Jul 20 2026 09:57 AM.

    What is the 52 Week High and Low of Novelix Pharmaceuticals Ltd?

    Answer Field

    The 52 Week High and Low of Novelix Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 92.00 and ₹ 38.00.

    What is 1 year return for Novelix Pharmaceuticals Ltd?

    Answer Field

    The 1 year returns on the stock has been 38.27%.

    What is the P/E Ratio of Novelix Pharmaceuticals Ltd Share?

    Answer Field

    As on Jul 20 2026 09:57 AM the price-to-earnings (PE) ratio for Novelix Pharmaceuticals Ltd share is 70.29.

    What is the PB ratio of Novelix Pharmaceuticals Ltd Share?

    Answer Field

    As on Jul 20 2026 09:57 AM, the price-to-book (PB) ratio for Novelix Pharmaceuticals Ltd share is 23.07.

    How to Buy Novelix Pharmaceuticals Ltd Share?

    Answer Field

    You can trade in Novelix Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Novelix Pharmaceuticals Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Novelix Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Novelix Pharmaceuticals Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |